SpePharm has launched MuGard in Norway. The company’s new move follows previous commercial launches in the UK, Germany, Italy and Greece.
Under a license from Access, SpePharm is responsible for manufacturing, regulatory approval and commercialization in 27 European countries.
SpePharm plans to launch MuGard throughout Europe over the next 12 months, with direct launches planned in France, Spain and the Benelux countries, as well as through local distributors in Central and Eastern Europe. The license agreement includes royalties on net sales to Access.
Jeffrey Davis, president and CEO of Access, said: “The early feedback includes a high rate of enthusiasm and intention to continue use by practicing clinicians and patients, who have used MuGard.”
“We believe this enhanced awareness of the benefits associated with use of MuGard as a preventative treatment is likely to result in solid marketing traction and market penetration in Europe as SpePharm continues market seeding studies in the major EU markets to continue to develop awareness within the medical community. Access continues to aggressively seek ways to maximize MuGard’s potential for cancer patients and for its shareholders,” he added.